表紙
市場調査レポート

世界のハンチントン病治療薬市場の将来動向

Global Huntington's Disease Therapeutics Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 317294
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界のハンチントン病治療薬市場の将来動向 Global Huntington's Disease Therapeutics Market 2014-2018
出版日: 2014年10月22日 ページ情報: 英文 72 Pages
概要

ハンチントン病とは進行性の神経変性障害で、遺伝子優勢な特質があるため、1つの世代から次の世代へと遺伝していく可能性があります。この疾患は、脳の一部(大脳基底核・大脳皮質など)の神経細胞に遺伝的にプログラムされた変形が生じることで発症します。大脳基底核が運動調整で重要な役割を果たす一方、大脳皮質は認識・思考・記憶をつかさどっています。神経細胞が変形することで、認知障害が段階的に進行していきます。また、ハンチントン病の患者はしばしば舞踏病(手・顔・胴体・足の筋肉の不随意運動)も発症します。この疾患に伴う行動障害として、うつ病や精神障害、人格の変化などが挙げられます。他にも、言語障害や不安症、ストレス、嚥下障害といった症状も現れます。ハンチントン病の患者は、通常は30〜40歳代に発症しますが、稀に幼児期や少年期に発症する場合もあります。前者を成人発症型、後者を早期発症型と呼びますが、早期発症型は他の症状(振戦、動作の遅さ、身体硬直など)と関連性があります。早期発症型の患者が成人期まで生き延びることはあまりありません。現在、ハンチントン病に対する有効な治療法は見つかっていません。世界のハンチントン病治療薬市場の2013〜2018年の年平均成長率(CAGR)は29.46%に達する見通しです。

当レポートでは、全世界のハンチントン病治療薬の市場について分析し、市場の概要や構造、市場規模の動向(今後5年間の予測値)、薬物クラス別・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・考察しております。

第1章 エグゼクティブ・サマリー

第2章 略語集

第3章 分析範囲

  • 市場概要
  • 主な製品

第4章 市場分析の手法

  • 市場分析のプロセス
  • 分析手法

第5章 イントロダクション

第6章 ハンチントン病の有病者数

第7章 市場環境

  • 市場概況
  • 市場規模とその予測
  • ファイブフォース分析

第8章 薬物クラス別の市場分析

第9章 地域別の分析

第10章 購入基準

第11章 市場の成長促進要因

第12章 促進要因とその影響力

第13章 市場の課題

第14章 促進要因・課題の影響力

第15章 市場の傾向

第16章 市場動向とその影響

第17章 ベンダー環境

  • 競争シナリオ
    • 近年の主な動向
  • 市場シェア分析
  • 将来的な有力ベンダー

第18章 治験段階のパイプライン候補薬

第19章 治験段階のパイプライン候補薬の主要データ

  • SD-809ER
  • RP103
  • ABR-215062
  • BN82451
  • OMS824
  • PF-02545920
  • SEN0014196
  • TV-7820
  • PBT2
  • GSK356278
  • PBF-999

第20章 治験が中止されたパイプライン医薬品

第21章 主要ベンダーの分析

  • H. Lundbeck
    • 主要データ
    • 事業概要
    • 部門別の市場収益額(最新値)
    • 部門別の市場収益額(前年度との比較)
    • 地域別の市場収益額
    • 事業戦略
    • 近年の動向
    • SWOT分析
  • Valeant Pharmaceuticals International

第22章 その他の関連分析

図表一覧

目次
Product Code: IRTNTR4355

About Huntington's Disease

Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. People with Huntington's disease often develop chorea that causes involuntary muscle movements of hands, face, trunk, and feet. The behavioural disorders associated with the disease include depression, psychosis, and changes in personality. Other symptoms of the disease include speech impairment, anxiety, stress, and difficulty in swallowing. People suffering from Huntington's disease usually develop symptoms in their mid-30s and 40s. However, in few cases, disease symptoms appear in childhood or teens. The former case represents the adult-onset form of the disease, while the latter is the early-onset form. The early-onset form is associated with symptoms such as tremors, slow movements, and rigidity. Children with early-onset disease rarely live to adulthood. Currently, there is no approved treatment for Huntington's disease.

TechNavio's analysts forecast the Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Huntington's Disease Therapeutics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of drugs approved for the treatment of symptoms of Huntington's disease.

TechNavio's report, the Global Huntington's Disease Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Huntington's Disease Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Lundbeck
  • Valeant Pharmaceuticals International

Other Prominent Vendors

  • Auspex Pharmaceuticals
  • GlaxoSmithKline
  • Ipsen
  • Omeros
  • Palobiofarma
  • Pfizer
  • Prana Biotechnology
  • Raptor Pharmaceutical
  • Siena Biotech
  • SOM Biotech
  • Teva Pharmaceutical Industries

Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Market Challenge

  • Poor Diagnosis Rates
  • For a full, detailed list, view our report

Market Trend

  • Novel Mechanisms Targeted by Pipeline Candidates
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Prevalence of Huntington's Disease

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Drug Class

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
  • 17.2. Market Share Analysis 2013
  • 17.3. Potential Future Vendors

18. Clinical-stage Pipeline Candidates

19. Key Information of Clinical-stage Pipeline Candidates

  • 19.1. SD-809ER
  • 19.2. RP103
  • 19.3. ABR-215062
  • 19.4. BN82451
  • 19.5. OMS824
  • 19.6. PF-02545920
  • 19.7. SEN0014196
  • 19.8. TV-7820
  • 19.9. PBT2
  • 19.10. GSK356278
  • 19.11. PBF-999

20. Discontinued Clinical-stage Pipeline Drugs

21. Key Vendor Analysis

  • 21.1. H. Lundbeck
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Product Segmentation by Revenue 2013
    • 21.1.4. Product Segmentation by Revenue 2012 and 2013
    • 21.1.5. Geographical Segmentation by Revenue 2013
    • 21.1.6. Business Strategy
    • 21.1.7. Recent Developments
    • 21.1.8. SWOT Analysis
  • 21.2. Valeant Pharmaceuticals International
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation by Revenue 2013
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Sales by Geography
    • 21.2.6. Business Strategy
    • 21.2.7. Key Developments
    • 21.2.8. SWOT Analysis

22. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Prevalence of Huntington's Disease by Geography 2013
  • Exhibit 3: Global Huntington's Disease Therapeutics Market 2013-2018 (US$ million)
  • Exhibit 4: Global Huntington's Disease Therapeutics Market by Drug Class
  • Exhibit 5: Global Huntington's Disease Therapeutics Market by Geographical Segmentation 2013
  • Exhibit 6: Global Huntington's Disease Therapeutics Market Share Analysis 2013
  • Exhibit 7: Key Regulatory Approvals of Tetrabenazine
  • Exhibit 8: Key Events of Xenazine
  • Exhibit 9: Valeant Pharmaceuticals International Inc.: Sales of Xenazine 2008-2013 (US$ million)
  • Exhibit 10: Valeant Pharmaceuticals International Inc.: Sales of Xenazine by Geography 2013
  • Exhibit 11: H. Lundbeck A/S: Sales of Xenazine 2009-2013 (US$ million)
  • Exhibit 12: H. Lundbeck A/S: Quaterly Sales of Xenazine 2009-2013 (US$ million)
  • Exhibit 13: H. Lundbeck: Business Segmentation by Revenue 2013
  • Exhibit 14: H. Lundbeck: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 15: H. Lundbeck: Geographical Segmentation by Revenue 2013
  • Exhibit 16: Valeant Pharmaceuticals International Inc.: Business Segmentation by Revenue 2013
  • Exhibit 17: Valeant Pharmaceuticals International Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 18: Valeant Pharmaceuticals International Inc.: Sales by Geography 2013
Back to Top